We recently showed that downregulation of SPRED2 in HCC promotes tumor cell proliferation, EMT, stemness, and anti-apoptotic properties, and leads to more malignant phenotypes through increased activation of MAPK/ERK [8]. This evidence concerns the gene SPRED2 and hepatocellular carcinoma.